Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 yearsHong Liu-Seifert, Eric Siemers, Karen C Holdridge, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 5, 2015
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patientsEric R Siemers, Karen L Sundell, Christopher Carlson, et al.The New England Journal of Medicine|January 24, 2014
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's diseaseRachelle S Doody, Ronald G Thomas, Martin Farlow, et al.Alzheimer'S Research & Therapy|June 30, 2015
Alzheimer's disease progression by geographical region in a clinical trial settingDavid B Henley, Sherie A Dowsett, Yun-Fei Chen, et al.The Journal of Clinical Psychiatry|June 6, 2009
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior responseJean-Pierre Lindenmayer, Hong Liu-Seifert, Pandurang M Kulkarni, et al.Annals of the Rheumatic Diseases|September 30, 2019
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trialPhilip J Mease, Josef S Smolen, Frank Behrens, et al.Alzheimer'S Research & Therapy|June 30, 2015
Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trialsJoshua D Grill, Rema Raman, Karin Ernstrom, et al.Journal of Clinical Psychopharmacology|July 16, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose studyBruce J Kinon, Jan Volavka, Virginia Stauffer, et al.The New England Journal of Medicine|January 25, 2018
Trial of Solanezumab for Mild Dementia Due to Alzheimer's DiseaseLawrence S Honig, Bruno Vellas, Michael Woodward, et al.Pageof 4